無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アジア太平洋地域のバイオシミラー市場の予測:〜2025年

APAC Biosimilar Market, Forecast 2025

発行 Frost & Sullivan 商品コード 602441
出版日 ページ情報 英文 160 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.02円で換算しております。
Back to Top
アジア太平洋地域のバイオシミラー市場の予測:〜2025年 APAC Biosimilar Market, Forecast 2025
出版日: 2018年01月10日 ページ情報: 英文 160 Pages
概要

当レポートでは、アジア太平洋地域のバイオシミラーの市場を調査し、市場の発展の経緯、バイオシミラーの導入推進因子と障壁、 アジアの重要性、収益・収益シェアの予測、主要薬剤・国別の詳細分析、成長機会・成功戦略の分析などをまとめています。

第1章 エグゼクティブダッシュボード

第2章 成長環境:市場概要

  • 市場概要
  • バイオシミラー市場の主要課題
  • バイオシミラー市場の発展の経緯
  • 治療分野別の分類
  • 市場動向
  • 特許動向
  • バイオシミラー導入への影響エリア
  • 医師による導入を阻む因子
  • 推進因子と障壁
  • 影響マッピング

第3章 バイオシミラー市場の予測

  • 市場概要
  • 収益シェア予測:地域別
  • 収益予測
  • 収益予測:分子タイプ別
  • 収益予測に関するディスカッション

第4章 成長パイプライン・戦略・実装

  • 主な成長機会
  • 成長機会:癌のmAbバイオシミラー
  • 成長機会:糖尿病のインスリングラルギンバイオシミラー
  • 成長機会:関節リウマチのmAbバイオシミラー
  • 成功・成長の戦略的必須要件

第5章 癌:トラスツズマブバイオシミラー

  • 主要参入事業者
  • 収益予測
  • 導入率・患者人口
  • 価格・ディスカウント

第6章 癌:ベバシズマブバイオシミラー

  • 主要参入事業者
  • 収益予測
  • 導入率・患者人口
  • 価格・ディスカウント

第7章 糖尿病:インスリングラルギンバイオシミラー

  • 主要参入事業者
  • 収益予測
  • 導入率・患者人口
  • 価格・ディスカウント

第8章 関節リウマチ:エタネルセプトバイオシミラー

  • 主要参入事業者
  • 収益予測
  • 導入率・患者人口
  • 価格・ディスカウント

第9章 関節リウマチ:インフリキシマブバイオシミラー

  • 主要参入事業者
  • 収益予測
  • 導入率・患者人口
  • 価格・ディスカウント

第10章 関節リウマチ:アダリムマブバイオシミラー

  • 主要参入事業者
  • 収益予測
  • 導入率・患者人口
  • 価格・ディスカウント

第11章 市場力学

  • 豊富な市場機会
  • 法規制当局
  • アジア太平洋地域のゲームチェンジャー
  • ブロックバスターバイオ医薬品の特許失効
  • 市場の将来性
  • 市場分析
  • 注目の企業、など

第12章 中国市場

  • 収益予測
  • 収益予測に関するディスカッション
  • 市場分析
  • 参入事業者の概要
  • 法規制環境
  • 戦略的必須要件

第13章 インド市場

  • 収益予測
  • 収益予測に関するディスカッション
  • 市場分析
  • 参入事業者の概要
  • 法規制環境
  • 戦略的必須要件

第14章 韓国市場

  • 収益予測
  • 収益予測に関するディスカッション
  • 市場分析
  • 参入事業者の概要
  • 法規制環境
  • 戦略的必須要件

第15章 日本市場

  • 収益予測
  • 収益予測に関するディスカッション
  • 市場分析
  • 参入事業者の概要
  • 法規制環境
  • 戦略的必須要件

第16章 オーストラリア市場

  • 収益予測
  • 収益予測に関するディスカッション
  • 市場分析
  • 参入事業者の概要
  • 法規制環境
  • 戦略的必須要件

第17章 総論

第18章 付録

第19章 バイオシミラー市場の発展

目次
Product Code: P9A3-52

Patent Expiries, Defined Regulatory Pathways, and Escalating Healthcare Costs to Boost Growth

Biosimilars is a massive opportunity; regardless of a slow start, the market will eventually be a huge business. As per Frost & Sullivan's estimate, biologic drugs worth $70-$80 billion will lose exclusivity in the next 5 years globally and APAC's contribution would be more than 20%. Countries in the region, such as India, China, and South Korea, offer an attractive opportunity for drug development and commercialization. Moreover, these are generics-driven markets, providing a positive opportunity for biosimilars development and commercialization.

Research Highlights:

The launch of innovative production platforms will reduce the cost of biosimilar production, thus providing substantial price differentiation. In the next 4-5 years, two-thirds of the patent expiries would be in biosimilars and specialty segments such as bio-betters that have high profit margins.

High revenue-churning blockbuster drugs are set to lose their patent protection in APAC during the forecast period and biosimilars companies are proactive in filing applications for marketing rights. In the pharmaceuticals market, there is a shift towards higher-value biological therapies, biosimilars, and specialty segments, where there is less competition despite high profit margins. With several biological drugs expected to lose patents by 2020, this segment is expected to experience an annual growth rate of more than 30.0% by 2020. Many Asian companies have biosimilars molecules under development, such as LG Life Sciences, Samsung Bioepis, and Celtrion. Cipla has already launched the biosimilar version in India in 2013, followed by Intas Pharmaceuticals in March 2015. Samsung Bioepis has also received approval for its biosimilar in South Korea in September 2015 for entracept.

Key Features:

The key objective of this research service is to help clients identify the major growth opportunities for biosimilars across therapeutic areas such as rheumatoid arthritis, cancer, and diabetes, and understand the key challenges in the space.

Key Issues Addressed:

  • What is the current scenario of the biosimilars market in APAC, and how far will it grow?
  • What are the key factors driving the market, and what are the barriers that need to be resolved?
  • Which are the key market segments to look out for, and what are the key trends and regulatory aspects?
  • Who are the key market participants involved, and where do they stand?
  • What are the factors affecting the biosimilars market in the different regions of APAC, and how will these factors affect the market?
  • What is the future of the biosimilars market in Asia?

Table of Contents

1. EXECUTIVE DASHBOARD

  • Purpose of the Experiential Study
  • 5 Step Process to Transformational Growth
  • Scope and Segmentation
  • Key Questions This Study Will Answer
  • Key Findings
  • Biosimilars-Gateway to Success
  • Trends in Evolving Biopharmaceuticals Market
  • Biosimilars Ecosystem-Industry Convergence Map
  • Ecosystem Partnerships
  • Disruptive Trends in the Changing Market Landscape
  • Key Regions
  • Six Big Market Themes for Global Biosimilars Market

2. GROWTH ENVIRONMENT-MARKET OVERVIEW

  • Market Overview
  • Key Challenges in the Biosimilars Market
  • Biosimilars Market-Timeline
  • Market Segmentation by Therapeutic Areas
  • Trends in Global Biosimilars Market
  • Global Biosimilar Patenting Trends
  • Areas Impacting Biosimilars Adoption
  • Attributes Impeding Physician Adoption of Biosimilars
  • Drivers and Restraints
  • Impact Mapping of Drivers and Restraints

3. BIOSIMILARS MARKET FORECASTS

  • Market Snapshot-Biosimilars Market
  • Percent Revenue Forecast by Region
  • Revenue Forecast
  • Revenue Forecast by Molecule Type
  • Revenue Forecast Discussion

4. GROWTH PIPELINE, STRATEGY, AND IMPLEMENTATION

  • Major Growth Opportunities
  • Growth Opportunity 1-mAb Biosimilars for Cancer
  • Growth Opportunity 2-Insulin Glargine Biosimilars for Diabetes
  • Growth Opportunity 3-mAb Biosimilars for Rheumatoid Arthritis
  • Strategic Imperatives for Success and Growth

5. ONCOLOGY-TRASTUZUMAB BIOSIMILARS

  • Trastuzumab Biosimilars-Key Participants
  • Trastuzumab Biosimilars-Revenue Forecast
  • Trastuzumab Biosimilars-Adoption Rate and Patient Population
  • Trastuzumab Biosimilars-Price and Discounts

6. ONCOLOGY-BEVACIZUMAB BIOSIMILARS

  • Bevacizumab Biosimilar-Key Participants
  • Bevacizumab Biosimilar-Revenue Forecast
  • Bevacizumab Biosimilar-Adoption Rate and Patient Population
  • Bevacizumab Biosimilar-Price and Discounts

7. DIABETES-INSULIN GLARGINE BIOSIMILARS

  • Insulin Glargine Biosimilar-Key Participants
  • Insulin Glargine Biosimilar-Revenue Forecast
  • Insulin Glargine Biosimilar-Adoption Rate and Patient Population
  • Insulin Glargine Biosimilar-Price and Discounts

8. RHEUMATOID ARTHRITIS-ETANERCEPT BIOSIMILARS

  • Etanercept Biosimilar-Key Participants
  • Etanercept Biosimilar-Revenue Forecast
  • Etanercept Biosimilar-Adoption Rate and Patient Population
  • Etanercept Biosimilar-Price and Discounts

9. RHEUMATOID ARTHRITIS-INFLIXIMAB BIOSIMILARS

  • Infliximab Biosimilar-Key Participants
  • Infliximab Biosimilar-Revenue Forecast
  • Infliximab Biosimilar-Adoption Rate and Patient Population
  • Infliximab Biosimilar-Price and Discounts

10. RHEUMATOID ARTHRITIS-ADALIMUMAB BIOSIMILARS

  • Pipeline for Adalimumab Biosimilar-Key Participants
  • Adalimumab Biosimilar-Revenue Forecast
  • Adalimumab Biosimilar-Adoption Rate and Patient Population
  • Adalimumab Biosimilar-Price and Discounts

11. BIOSIMILARS MARKET DYNAMICS-WHY ASIA?

  • APAC-A Lucrative Market for Biosimilars
  • APAC-Regulatory Authorities
  • APAC Biosimilars-Game-changing Companies
  • Patent Expiry for Blockbuster Bio-pharmaceuticals
  • APAC-Future of Biosimilars
  • APAC-Market Analysis
  • Transformation of Industry Ecosystem
  • Key Factors for New Entrants
  • Interchangeability
  • Interchangeability (continued)
  • Regional Hot Spots
  • Country Attractiveness
  • Key Companies to Watch
  • Mergers, Acquisitions, and Partnerships Assessment
  • Mergers, Acquisitions, and Partnerships Assessment (continued)
  • Strategies for Foreign Participants in APAC
  • Factors Influencing Uptake of Biosimilars in APAC
  • Factors Influencing Uptake of Biosimilars in APAC-Discussion
  • Physicians, Patients, and Pharmacists-Perceptions and Concerns

12. BIOSIMILARS MARKET-CHINA

  • Revenue Forecast
  • Revenue Forecast Discussion
  • Market Analysis
  • Snapshot of Market Participants
  • Regulatory Environment
  • Strategic Imperatives for China-Key Trends

13. BIOSIMILARS MARKET-INDIA

  • Revenue Forecast
  • Revenue Forecast Discussion
  • Snapshot of Market Participants
  • Regulatory Environment
  • Strategic Imperatives for India-Key Trends
  • Growth Potential of Key Segments in Bio-tech in India

14. BIOSIMILARS MARKET-SOUTH KOREA

  • Revenue Forecast
  • Revenue Forecast Discussion
  • Revenue Forecast Discussion (continued)
  • Snapshot of Market Participants
  • Regulatory Environment
  • Regulatory Environment (continued)
  • Strategic Imperatives for South Korea-Key Trends

15. BIOSIMILARS MARKET-JAPAN

  • Revenue Forecast
  • Revenue Forecast Discussion
  • Snapshot of Market Participants
  • Regulatory Environment
  • Regulatory Environment (continued)
  • Strategic Imperatives for Japan-Key Trends

16. BIOSIMILARS MARKET-AUSTRALIA

  • Revenue Forecast
  • Revenue Forecast Discussion
  • Snapshot of Market Participants
  • Regulatory Environment
  • Strategic Imperatives for Australia-Key Trends

17. CONCLUSION

  • Visioning Scenarios for the Biosimilars Market
  • Visioning Scenarios for the Biosimilars Market (continued)
  • Visioning Scenarios for the Biosimilar Market (continued)
  • Visioning Scenarios for the Biosimilars Market (continued)
  • Business Model Essentials
  • 5 Competitive Keys for Success
  • Future of Biosimilars in APAC
  • Legal Disclaimer

18. APPENDIX

  • List of Exhibits
  • List of Exhibits (continued)
  • List of Exhibits (continued)
  • List of Exhibits (continued)
  • List of Exhibits (continued)
  • List of Exhibits (continued)
  • Global Regulatory Landscape
  • Global Regulatory Landscape Discussion
  • Regulations and their Impact on the Biosimilars Market

19. BIOSIMILARS-MARKET EVOLUTION

  • Biosimilars are Not Generics-A Comparison Between Generics, Biologics, and Biosimilars
  • Biosimilars are Not Generics-A Comparison Between Generics, Biologics, and Biosimilars (continued)
  • Biosimilars are Not Generics-A Comparison Between Generics, Biologics, and Biosimilars (continued)
  • Biologics and Biosimilars-Manufacturing Processes
  • Development Process and Technical Requirements for BiosimilarsProduction process and technical needs are complex.
  • Timeline for Development of a Biosimilar Medicine
  • Value Chain Analysis-Development of a Biosimilar
  • Big Pharma Companies (Innovators) Vs Biotech Firms Vs Generic Manufacturers
Back to Top